LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $33.6M (cash outflow) rose 107.9% year over year, ahead of the +67.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 1.6% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.

Context

  • Free cash flow amounted to 366.7% of revenue in FY2025.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +107.9% holds above the trailing-twelve-month pace of +67.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$33.6M+1.6% QoQ
Last fiscal yearDec 2025
-$70M+16.9% YoY
LTMMar 2026
-$87.44M+67.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.9%——
1 year+16.9%——
3-year CAGR-9.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(70M) USD
Year-over-year change
-16.9%

Free Cash Flow vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.9% is the 2nd highest of 11, against a peer median of +12.3%.
  • Free cash flow amounts to 416.6% of revenue for LENZ, versus a peer median of 89.5%.
LENZ Competitors
Free Cash Flow for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$175.32M USD+732.7%+62.0%177.1%
PRMEPrime Medicine, Inc.LTM Mar 2026$158.74M USD+42.5%+4.1%3935.1%
GERNGeron CorporationLTM Mar 2026$126.3M USD-38.2%-4.6%64.4%
SVRASavara Inc.LTM Mar 2026$106.97M USD+11.8%+43.0%—
TYRATyra Biosciences, Inc.LTM Mar 2026$102.47M USD+38.9%+23.3%—
LENZLENZ Therapeutics, Inc.LTM Mar 2026$87.44M USD+67.9%-9.5%416.6%
RZLTRezolute, Inc.LTM Mar 2026$73.48M USD+12.0%+20.4%—
GHRSGH Research PLCLTM Mar 2026$46.51M USD+12.6%+18.5%—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$35.11M USD-21.5%—16.8%
ABUSArbutus Biopharma CorporationLTM Mar 2026$34.36M USD-41.8%+3.4%17.9%
NBTXNanobiotix S.A.FY2025€33.97M EUR+66.5%-3.0%114.6%
Peer median (excluding LENZ) —+12.3%+18.5%89.5%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.76M)(101.05M)(69.97M)(49.77M)(82.13M)
Depreciation & Amortization734K8.35M15K58K(3.12M)
Deferred Income Tax00000
Stock-Based Compensation001.34M6.37M12.55M
Change in Working Capital(2.5M)(7.21M)9.41M(13.09M)3.25M
Accounts Receivables0000(329K)
Inventory0000(4.28M)
Accounts Payables1.83M194K856K(4.28M)(90K)
Other Working Capital(4.32M)(7.4M)8.55M(8.81M)7.95M
Other Non-Cash Items19.67M11.93M(1.18M)(2.95M)279K
Operating Cash Flow(52.85M)(87.98M)(60.38M)(59.39M)(69.17M)
Capital Expenditures(5.74M)(6.59M)(30K)(468K)(827K)
Acquisitions (Net)00000
Purchases of Investments0(405.52M)(52.09M)(241.91M)(280.8M)
Sales of Investments0170.25M22.5M87.9M205.96M
Other Investing Activities00000
Investing Cash Flow(5.74M)(241.86M)(29.62M)(154.48M)(75.67M)
Debt Repayment00000
Common Stock Issued417.16M676K203K79.51M149.75M
Common Stock Repurchased0(79K)000
Dividends Paid00000
Other Financing Activities306K0(2.48M)119.49M0
Financing Cash Flow417.47M597K80.7M199M149.75M
Effect of Forex Changes(1.72M)0000
Net Change in Cash357.16M(329.25M)(9.3M)(14.87M)4.91M
Free Cash Flow(58.59M)(94.57M)(60.41M)(59.86M)(70M)

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.